Radiotherapy Quality Assurance for the CHHiP Trial: Conventional Versus Hypofractionated High-Dose Intensity-Modulated Radiotherapy in Prostate Cancer

Autor: C. South, Helen Mayles, K Roberts, Emma Hall, Shama Hassan, Sarah L. Gulliford, CHHiP Investigators, Catharine H. Clark, Khoo, David P. Dearnaley, M. Bidmead, O. Naismith

Publikováno v: Clinical Oncology. 31:611-620

Aims The CHHiP trial investigated the use of moderate hypofractionation for the treatment of localised prostate cancer using intensity-modulated radiotherapy (IMRT). A radiotherapy quality assurance programme was developed to assess compliance with t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f315ac65561b66b2dd4f31e8ac833e92
https://doi.org/10.1016/j.clon.2019.05.009

A multicentre ‘end to end’ dosimetry audit for cervix HDR brachytherapy treatment

Autor: P. Diez, Andrew Nisbet, Andrea Wynn-Jones, D.A. Bradley, Peter Bownes, Chris Lee, M. Bidmead, Laura Gandon, Edwin Aird, Gerry Lowe, Antony L. Palmer

Publikováno v: Radiotherapy and Oncology. 114:264-271

Purpose To undertake the first multicentre fully 'end to end' dosimetry audit for HDR cervix brachytherapy, comparing planned and delivered dose distributions around clinical treatment applicators, with review of local procedures. Materials and metho

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7498da8b88a58605850d57b614c3b87f
https://doi.org/10.1016/j.radonc.2014.12.006

Final long-term results of a phase I/II study of dose-escalated intensity-modulated radiotherapy for locally advanced laryngo-hypopharyngeal cancers

Autor: M. Bidmead, Kate Newbold, Kevin J. Harrington, Aisha Miah, T.M. Richards, Catharine H. Clark, Ulrike Schick, Teresa Guerrero-Urbano, Liam Welsh, Lorna Grove, Shreerang Bhide, S. Bodla, Dorothy M. Gujral, Ceri Powell, Christopher M. Nutting

Publikováno v: Oral Oncology. 50:1089-1097

summary Objectives: We previously described dose-escalated intensity-modulated radiotherapy (IMRT) in squamous cell cancer of the larynx/hypopharynx (SCCL/H) to offer improved locoregional control with a low incidence of toxicity at 2 years. We now p

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::619def8357c2d383906653cc15ebe4df
https://doi.org/10.1016/j.oraloncology.2014.07.018

Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial

Autor: John Graham, Annie Gao, Isabel Syndikus, Alison Birtle, D. Bloomfield, Helen Patterson, Chris Parker, Helen Mayles, Helen Mossop, Clare Cruickshank, John P Logue, Shama Hassan, C. South, Julia Pugh, Zafar Malik, Clare Griffin, John Staffurth, Julian Money-Kyrle, Christopher D Scrase, Miguel Panades, O. Naismith, Emma Hall, Jean Tremlett, Andrew Stockdale, Vincent Khoo, Peter Kirkbride, David P. Dearnaley, M. Bidmead, Joe M. O'Sullivan

Publikováno v: Dearnaley, D, Syndikus, I, Mossop, H, Khoo, V, Birtle, A, Bloomfield, D, Graham, J, Kirkbride, P, Logue, J, Malik, Z, Money-Kyrle, J, O'Sullivan, J M, Panades, M, Parker, C, Patterson, H, Scrase, C, Staffurth, J, Stockdale, A, Tremlett, J, Bidmead, M, Mayles, H, Naismith, O, South, C, Gao, A, Cruickshank, C, Hassan, S, Pugh, J, Griffin, C, Hall, E & CHHiP Investigators 2016, ' Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial ', Lancet Oncology, vol. 17, no. 8, pp. 1047–1060 . https://doi.org/10.1016/S1470-2045(16)30102-4
The Lancet. Oncology

BACKGROUND: Prostate cancer might have high radiation-fraction sensitivity that would give a therapeutic advantage to hypofractionated treatment. We present a pre-planned analysis of the efficacy and side-effects of a randomised trial comparing conve

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7468fcd00b5e4c7f6098846e3e515575
https://pure.qub.ac.uk/en/publications/d7bcc256-159c-47a7-9e2e-b9dca853347d

Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial

Autor: Vincent Khoo, C. South, Annie Gao, Alan Horwich, Catharine H. Clark, Georges Sumo, P. Mayles, David P. Dearnaley, M. Bidmead, Robert Huddart, D. Bloomfield, Peter Kirkbride, Helen Mayles, John Staffurth, O. Naismith, Christopher D Scrase, Emma Hall, Chris Parker, Shama Hassan, Martin J. Russell, Helen Patterson, Isabel Syndikus

Publikováno v: The Lancet Oncology. 13(1):43-54

Summary Background Prostate cancer might have high radiation-fraction sensitivity, implying a therapeutic advantage of hypofractionated treatment. We present a pre-planned preliminary safety analysis of side-effects in stages 1 and 2 of a randomised

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::34354feace2290b2aa9566f54f982a6e